Current projects
An alphabetical list of all trials and studies currently being undertaken by the Cardiovascular Research Unit.
Most of our research relies on the generosity of patient volunteers.
If you would be interested in helping, email cvru@sheffield.ac.uk or call +44 114 226 6159.
A
ARTEMIS
A study comparing Ziltivekimab to placebo, given to patients within 36 hours of a heart attack, followed by a monthly injection of the study medication. The study will recruit 10,000 patients over 25 months, in over 630 centres worldwide.
Participants helping us with this study are currently under follow-up.
AZURE-Outcomes
A randomised, placebo controlled study to assess the effects of a novel drug called AZD0780 on major adverse cardiovascular events in patients with established cardiovascular disease, or at risk of first cardiovascular event.
AZD0780 is an oral PCSK9 inhibitor which we are comparing against a placebo.
This is a Phase 3 study, which will recruit 15,100 participants across approximately 1,000 study sites in 30 countries.
We are actively recruiting for this study. The link below provides more information. If you would like to take part, please get in touch with the research team on +44 114 2266159.
Learn more about AZURE-Outcomes
C
CLARITY PAD
A study to investigate the effectiveness of three antithrombotic regimens following lower-limb revascularisation for chronic limb-threatening ischaemia. The study is being run across 20 sites in the UK, including here in Sheffield.
We are actively recruiting for this study.
Find out more about CLARITY PAD
COMPLETE-2
Patients with a heart attack and multivessel coronary artery disease are randomised to either physiology-guided or angiography-guided revascularisation of non-culprit lesions. Our team will follow up on patients for an estimated 3.5 years.
The study is being conducted in approximately 140 centres worldwide.
CVRU-Obs
An observational study profiling thrombo-inflammatory parameters in patients with or at risk of cardiovascular disease. Patients for this study kindly agree to have an additional blood sample taken, along with a bleeding time measurement. The blood sample is processed in our specialised laboratory, characterising platelet function and the effects of antiplatelet medication.
E
EVEREST
Takotsubo cardiomyopathy is a heart condition that can be triggered by sudden emotional or physical stress causing stunning of part of the heart muscle. The EVEREST study is investigating whether or not it is beneficial to take a routinely-prescribed medication called ramipril after a Takotsubo event.
Half of the participants in EVEREST will continue ramipril, and half will not take this for at least two years after recovery from their event.
We are actively recruiting for this study. Please let the study team know if you would like further information.
F
FORTIFY
A phase 2 study, to determine the clinical effect of the study drug orticumab on inflammation in patients with a prior heart attack, and increased coronary inflammation, based on the results of a CCTA scan.
We are comparing the study drug to a placebo.
We are actively recruiting for this study. Please get in touch with the research team if you would like to take part.
H
HORIZON OLE
An open label extension of the HORIZON study. This will provide post-trial access to Pelacarsen in participants that have completed the main study.
This will also allow the evaluation of long term safety and tolerability of Pelacarsen.
L
LoDAT
The LoDAT study is only being conducted in Sheffield Teaching Hospitals.
Patients will be eligible for LoDAT if they have been diagnosed with atrial fibrillation and have just undergone stenting of the coronary arteries. We will be recruiting people who have been routinely prescribed a combination of the anticlotting medications apixaban and ticagrelor.
Participants will be randomised to either apixaban 5 mg BD or apixaban 2.5 mg BD alongside ticagrelor 90 mg BD.
We will assess if low-dose apixaban reduces bleeding tendency by performing a test known as bleeding time.
We are actively recruiting for this study.
M
MK0616-015
A study to evaluate efficacy and safety of study medication, MK0616 versus placebo, in reducing major adverse cardiovascular events in participants at high risk of further events. MK0616 is PCSK9 inhibitor which results in the reduction of LDL cholesterol.
The study is being conducted in approximately 600 centres worldwide. Participants taking part in Sheffield are actively being followed up.
O
ORION-4
A randomised trial to assess the effects on clinical outcomes of cholesterol-lowering injectable, inclisiran, among patients with a history of cardiovascular disease. Recruitment for this study has now ceased, although patients return to clinic for a 6-monthly injection.
S
SOS-AMI
A randomised controlled study to evaluate the efficacy and safety of the self-administered subcutaneous P2Y12 inhibitor selatogrel in patients with a recent history of acute myocardial infarction, at risk of having further myocardial infarction. This study is currently actively recruiting. We ask patients to self-inject should further symptoms of a heart attack occur.
V
VICTORION-1 PREVENT
A multi-centre, multi-country study, enrolling 14,000 patients at high risk of their first cardiovascular event. Patients are randomised to either inclisiran or placebo and receive 6 monthly injections at The Northern General Hospital. The aim is to compare the adverse event rate between the two treatment groups.
The patients helping us with this study are under follow-up and we are no longer recruiting.